NCT07819214Not yet recruitingPhase 2
Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI
Epcoritamab as Consolidation Therapy for High-risk Patients With Chronic Lymphocytic Leukemia on Bruton Tyrosine Kinase Inhibitor
Source: ClinicalTrials.gov · Last updated 14 Sept 2026
Brief summary (registry, in English)
This is a phase 2, single-arm, open-label clinical trial determining efficacy of Epcoritamab in subjects with Chronic Lymphocytic Leukemia (CLL) on Burton Tyrosine Kinase Inhibitor (BTKi).
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- First submitted
- 8 Sept 2026
- Start date
- Oct 2026
- Primary completion date
- Oct 2028
- Lead sponsor
- University of California, Irvine
- Diseases
- Chronic lymphocytic leukaemia
- NCT number
- NCT07819214
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 24
- From Oct 2026 to the primary completion date, Oct 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current or prior Richter's transformation
Other illness
- Second active malignancy requiring treatment (excluding non-melanamatous skin cancers and cancers requiring hormonal therapies alone such as breast/prostate cancer)
Other
- Active CNS involvement
- Active immune-mediated cytopenias
- Pregnant or breastfeeding
Who the study is looking for
- Patients with CLL and at least 1 of the following risk factors:
- ≥1 prior line of therapy before BTKi
- 17p deletion and/or TP53 mutation
- Complex karyotype (≥3 chromosomal abnormalities)
- Treated with a BTKi for ≥ 6 months
- Receiving or able to obtain a commercial supply of BTKi
- Measurable residual disease defined as the presence of CLL cells by conventional flow cytometry
- ALC ≤10 K/mcL
- Lymph nodes ≤5 cm in the longest diameter
- Normal organ function and hematologic parameters
- ECOG performance status of 0-1
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chao Family Comprehensive Cancer Center, University of California, Irvine Coordinator of this site? Confirm its status | Orange | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.